The end of animal testing? Transitioning to models is promising — but no silver bullet
The FDA has stated that the pharma industry must transition to using in vitro assays,…
Certara2025 年 7 月 21 日
制药行业是如何应对全球健康不平等问题的？
Explore Karen Rowland Yeo's insights on using Model-Informed Drug Development to address global health equities…
Certara2025 年 6 月 17 日
Redefining Regulatory Strategy with MIDD: Insights from the Draft ICH M15 Guidance
With the release of the draft ICH M15 guidance, MIDD is no longer optional -…
Certara2025 年 6 月 11 日
Evolving Regulatory Landscape for Model Informed Drug Development (MIDD): Impact of the Draft ICH M15 Guidance
SVP, PBPK Consultancy Services, Certara SVP, Quantitative Science Services, Certara Sr. Director, Clinical Pharmacology, Certara…
Certara2025 年 5 月 23 日
Certara’s Simcyp Educational Webinar Series: Learn from A to Z of PBBM Part 2: What is the Drug Absorption Model?
Part 3 in November: Understanding the Supersaturated Dissolution in the Digestive Tract with Modeling &…
Certara2025 年 5 月 12 日
Essentials of Model-informed Drug Development in Oncology
Model-informed drug development in oncology is critical to developing safer and more effective cancer drugs.…
Certara2025 年 5 月 2 日
Clinical and Physiologically Based Pharmacokinetic Model Evaluations of Adagrasib Drug–Drug Interactions
Director, Clinical Pharmacology, ORIC Pharmaceuticals SVP, Head of Simcyp PBPK Modeling Services, Certara Director, PBPK…
Certara2025 年 4 月 21 日
Enabling Personalized Therapy with PBPK Modeling for Pediatric Epilepsy
GRIN Therapeutics, Inc., an affiliate of Neurvati Neurosciences, focuses on the research and development of…
Certara2025 年 4 月 16 日
